Glioblastoma isn't a single mass but has finger-like 'tentacles' (diffuse infiltration) extending into brain tissue. It is also genetically and cellularly diverse, meaning a single-pathway drug will inevitably miss many tumor cells, leading to rapid recurrence and treatment failure.
The platform doesn't just transport a drug. The T-cells themselves populate the tumor microenvironment, which is naturally 'cold' (lacking immune cells) in glioblastoma. This increases inflammatory activity, making the tumor more susceptible to the delivered therapeutic payload.
To tap into public market investors, Adaptin Bio merged with a 'Form 10' public shell company. This distinct route is not a SPAC as it doesn't raise money in an IPO. Instead, it provides a faster path to becoming a public reporting entity to attract a wider investor base.
Glioblastoma evolves under therapeutic pressure, changing its expression and metabolism to resist treatment. Adaptin Bio's platform is designed to be adaptive, allowing them to switch therapeutic payloads (e.g., from APTN-101 to 102) as the tumor changes, effectively staying one step ahead.
While many cell therapies rely on complex genetic engineering with viral vectors, Adaptin Bio manipulates patient T-cells without it. This simpler, non-viral process is a strategic choice to reduce costs, speed up manufacturing, and make the therapy accessible to a broader patient population.
The T-cell delivery system is versatile. It can carry T-cell engagers for cancer, but also antibodies for Alzheimer's or oligonucleotides. By using different T-cell types (like regulatory T-cells), it can also be used to reduce inflammation, expanding its applicability beyond oncology.